Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers using its small molecule nucleotide platform. The company is developing its product candidate, inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus. The company has designed its antiviral product candidates, including inarigivir, to selectively activate within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.